Premium
Intravitreal bevacizumab (Avastin) in treating macular oedema associated with central retinal vein occlusion
Author(s) -
ADEPEGBA O,
GEORGE S
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.337.x
Subject(s) - medicine , pro re nata , visual acuity , ophthalmology , bevacizumab , central retinal vein occlusion , fundus (uterus) , fundus fluorescein angiography , fluorescein angiography , retinal , occlusion , macular edema , surgery , ranibizumab , chemotherapy
Purpose To report the response following intravitreal bevacizumab(IVB) therapy in macula oedema associated with central retinal vein occlusion(CRVO). Methods Clinic charts of consecutive patients with macula oedema secondary to CRVO were retrospectively reviewed. Data from ophthalmological examination, Visual acuity, OCT (optical coherence tomography) fundus fluorescein angiography were recorded. All patient received one intravitreal bevacizumab 1.25mg/0.05ml at baseline and retreatment was on prn (pro re nata ) basis. Results Twenty‐five eyes of 25 eyes of 25 patients with a mean age of 73.1±12.1 were reviewed. Average time between diagnosis and initiation of IVB was 9.3±8.2weeks(range=0‐52weeks). Follow up was 12 months. All patients were treatment naïve. Mean baseline visual acuity and central retinal thickness(CRT) was 32.5±7.2ETDRS letters and 625±240µ respectively. The mean change in in vision at month 1, 3, 6 and 12 was + 4.5(p=0.10), +9.6(0.051), +11(p=0.062) and 13.6(p=0.049) ETDRS letters respectively. The mean change in CRT from baseline at month one was ‐209µ(p=0.056) and ‐335µ(p=0.009), ‐263µ(p=0.03) and ‐258µ(p=0.022) at month 3, 6 and 12 respectively. Mean number of injection was 3.4 at month 6 and 5.2 at month 12. There were no complications recorded. Conclusion Treatment of macula oedema secondary to CRVO with IVB resulted in improvement of visual acuity and significant decrease in macula oedema over 12 follow up.